Abstract:Abstract The global pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) created a rush to discover drug candidates. Despite the efforts, so far no vaccine or drug has been approved for treatment. Artificial intelligence offers solutions that could accelerate the discovery and optimization of new antivirals, especially in the current scenario dominated by the scarcity of compounds active against SARS-CoV-2. The main protease (M pro ) of SARS-CoV-2 is an attractive target for drug discovery due to the absence in humans and the essential role in viral replication. In this work, we developed a deep learning platform for de novo design of putative inhibitors of SARS-CoV-2 main protease (M pro ). Our methodology consists of 3 main steps: (1) training and validation of general chemistry-based generative model; (2) fine-tuning of the generative model for the chemical space of SARS-CoV- M pro inhibitors and (3) training of a classifier for bioactivity prediction using transfer learning. The fine-tuned chemical model generated > 90% valid, diverse and novel (not present on the training set) structures. The generated molecules showed a good overlap with M pro chemical space, displaying similar physicochemical properties and chemical structures. In addition, novel scaffolds were also generated, showing the potential to explore new chemical series. The classification model outperformed the baseline area under the precision-recall curve, showing it can be used for prediction. In addition, the model also outperformed the freely available model Chemprop on an external test set of fragments screened against SARS-CoV-2 Mpro, showing its potential to identify putative antivirals to tackle the COVID-19 pandemic. Finally, among the top-20 predicted hits, we identified nine hits via molecular docking displaying binding poses and interactions similar to experimentally validated inhibitors.

De Novo Drug Design Against SARS-CoV-2 Protein Targets Using SMILES-based Deep Reinforcement Learning.

AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2

De Novo Generation of Dual-Target Ligands for the Treatment of SARS-CoV-2 Using Deep Learning, Virtual Screening, and Molecular Dynamic Simulations.

Identification of SARS-CoV-2 Mpro inhibitors through deep reinforcement learning for de novo drug design and computational chemistry approaches

De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning

Artificial Intelligence-Guided De Novo Molecular Design Targeting COVID-19

De Novo Design and Bioactivity Prediction of SARS-CoV-2 Main Protease Inhibitors Using ULMFit

Utilizing artificial intelligence for precision exploration of N protein targeting phenanthridine sars-cov-2 inhibitors: A novel approach

A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism

Deep Learning-Based Molecular Dynamics Simulation for Structure-Based Drug Design Against SARS-CoV-2

Predicting drug-Protein interaction with deep learning framework for molecular graphs and sequences: Potential candidates against SAR-CoV-2

De Novo design of potential inhibitors against SARS-CoV-2 Mpro

CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models

De Novo Structure-Based Drug Design Using Deep Learning

Universal Approach to De Novo Drug Design for Target Proteins Using Deep Reinforcement Learning

De novo design of novel spike glycoprotein inhibitors using e-pharmacophore modeling, molecular hybridization, ADMET, quantum mechanics and molecular dynamics studies for COVID-19

De novo Drug Design using Reinforcement Learning with Multiple GPT Agents

Deep Learning Driven Drug Discovery: Tackling Severe Acute Respiratory Syndrome Coronavirus 2

Evolutionary Multi-Objective Design of SARS-CoV-2 Protease Inhibitor Candidates

Designing novel inhibitor derivatives targeting SARS-CoV-2 Mpro enzyme: a deep learning and structure biology approach